Nov 28, 2023

Official APPLIED MOLECULAR TRANSPORT INC. press release APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI November 28, 2023 at 05:20 pm EST Share Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH). Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-amti/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20231128767978/en/ Share Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company's pipeline includes AMT-101, and AMT-126. AMT-101 is a gastrointestinal-selective oral fusion of interleukin 10 (IL-10) and its proprietary carrier molecule that has been designed for active transport across the intestinal epithelium (IE) barrier into local gastrointestinal (GI) tissue. AMT-126 is a GI-selective oral fusion of interleukin 22 (IL-22) and its proprietary carrier molecule presently in development for diseases related to IE barrier function defects. Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs. Sector